Pay in 4 interest-free payments of $7.08 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
5 , A10A11 (2021)
The FDA has approved GLP-1 receptor agonists for type 2 diabetes management, with select agents (semaglutide/Wegovy and liraglutide/Saxenda) also approved for chronic weight management in adults with BMI 30 kg/m or 27 kg/m with at least one weight-related comorbidity
63 percent (29 decibels)
Prior authorization for Wegovy (semaglutide for weight loss) typically requires: Being obese, meaning a body mass index (BMI) of 30 or higher, or Being overweight (having a BMI of 27 or higher) with one or more weight-related health conditions such as diabetes, high blood pressure, or high cholesterol
And if your current prescriber is writing for Zepbound vials, ask whether the KwikPen is appropriate before July 1 to avoid a coverage gap
JabarpourMRashtchizadehNArganiHGhorbanihaghjoARanjbarzadhagMSanajouDet al
